Analysts Offer Predictions for DNLI FY2027 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Investment analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of Denali Therapeutics in a research note issued on Thursday, March 13th. Zacks Research analyst A. Chakraborty anticipates that the company will post earnings of ($2.25) per share for the year. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08.

DNLI has been the topic of several other reports. Bank of America cut their price objective on Denali Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Robert W. Baird began coverage on Denali Therapeutics in a report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price on the stock. B. Riley restated a “buy” rating and issued a $35.00 price target (down previously from $38.00) on shares of Denali Therapeutics in a report on Wednesday, March 5th. William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.20.

Denali Therapeutics Trading Up 1.9 %

NASDAQ:DNLI opened at $15.44 on Monday. The firm’s fifty day simple moving average is $20.17 and its 200 day simple moving average is $23.90. Denali Therapeutics has a twelve month low of $14.01 and a twelve month high of $33.33. The firm has a market capitalization of $2.24 billion, a price-to-earnings ratio of -5.59 and a beta of 1.46.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of DNLI. Sterling Capital Management LLC lifted its holdings in Denali Therapeutics by 589.9% in the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after acquiring an additional 1,516 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $62,000. Point72 Hong Kong Ltd bought a new stake in shares of Denali Therapeutics in the 4th quarter worth approximately $65,000. Quest Partners LLC acquired a new position in Denali Therapeutics during the 3rd quarter valued at approximately $73,000. Finally, PNC Financial Services Group Inc. grew its stake in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after buying an additional 885 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the sale, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. This represents a 11.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 47,940 shares of company stock worth $973,442. Corporate insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.